NASDAQ:CDXC
ChromaDex Corporation Stock News
$3.44
+0.0500 (+1.47%)
At Close: Apr 26, 2024
New Pilot Study Indicates Niagen® May Reduce Inflammatory Cytokines in Stage D Heart Failure Patients
10:32am, Tuesday, 18'th Aug 2020
ChromaDex Corp. (NASDAQ:CDXC) today announced the 11th published human trial on its patented NAD-boosting nutrient Niagen®, further highlighting its potential to support cardiovascular health in huma
ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates
11:10pm, Thursday, 06'th Aug 2020
ChromaDex (CDXC) delivered earnings and revenue surprises of 45.45% and 12.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
ChromaDex Corporation Reports Second Quarter 2020 Financial Results
08:01pm, Thursday, 06'th Aug 2020
ChromaDex Corp. (NASDAQ:CDXC) today reported second quarter 2020 financial results.
ChromaDex Corporation Reports Second Quarter 2020 Financial Results
12:00am, Thursday, 06'th Aug 2020
ChromaDex Corp. (NASDAQ:CDXC) today reported second quarter 2020 financial results. “We achieved record net sales of $15.3 million in the second quart
LD Micro - Announces Preliminary List of Presenters for the LD-500
01:00pm, Wednesday, 05'th Aug 2020
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively onlin
Will ChromaDex (CDXC) Report Negative Earnings Next Week? What You Should Know
04:33pm, Thursday, 30'th Jul 2020
ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ChromaDex to Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020
10:32am, Tuesday, 28'th Jul 2020
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., August 6, 2020 at 4:30 p.m. ET to discuss its financial results for the second quarter ended Jun. 30, 2020. The f
New Preclinical Study Finds Niagen® Corrects Social Deficits in Mouse Model of Autism
10:33am, Thursday, 16'th Jul 2020
ChromaDex Corp. (NASDAQ:CDXC) today announced the results of a new preclinical study published in Nature Scientific Reports investigating the role of Niagen® (patented nicotinamide riboside) in addre
Chromadex’s (CDXC) “Buy” Rating Reaffirmed at B. Riley
06:30pm, Wednesday, 15'th Jul 2020
Chromadex (NASDAQ:CDXC)‘s stock had its “buy” rating reiterated by equities research analysts at B. Riley in a research note issued on Tuesday, TipRanks reports. They presently have a $7.00 targ
ChromaDex External Research Program (CERP™) Achieves 200th Material Transfer Agreement for Niagen® (Nicotinamide Riboside) Research
10:32am, Tuesday, 14'th Jul 2020
ChromaDex Corp. (NASDAQ:CDXC) today announced the Company has signed its 200th material transfer agreement (MTA) through its global ChromaDex External Research Program (CERP™). The program provides
ChromaDex External Research Program (CERP™) Achieves 200th Material Transfer Agreement for Niagen® (Nicotinamide Riboside) Research
12:00am, Tuesday, 14'th Jul 2020
ChromaDex Corp. (NASDAQ:CDXC) today announced the Company has signed its 200th material transfer agreement (MTA) through its global ChromaDex External
Alliancebernstein L.P. Increases Stock Holdings in Chromadex Corp (NASDAQ:CDXC)
04:20am, Sunday, 12'th Jul 2020
Alliancebernstein L.P. increased its holdings in Chromadex Corp (NASDAQ:CDXC) by 92.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The
Zacks: Analysts Expect Chromadex Corp (NASDAQ:CDXC) Will Post Quarterly Sales of $13.56 Million
03:44am, Sunday, 12'th Jul 2020
Wall Street brokerages expect Chromadex Corp (NASDAQ:CDXC) to post $13.56 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates fo
ChromaDex Announces New Study Results Highlighting Promising Anti-Viral Effects of Niagen® in Coronavirus Cell Model
10:36am, Thursday, 09'th Jul 2020
ChromaDex Corp. (NASDAQ:CDXC) today announced the latest preclinical findings indicating Niagen® (patented nicotinamide riboside) inhibits replication of a form of Coronavirus, the virus that causes
ChromaDex Corp. (NASDAQ:CDXC) announced today the initiation of a preclinical study in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National
